{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:50:51Z","timestamp":1793875851438,"version":"4.7.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune-mediated rheumatologic and musculoskeletal diseases (RMDs) comprise a heterogeneous group of systemic conditions that affect the connective tissues of the musculoskeletal system and internal organs. Immune-mediated RMDs are driven by chronic autoimmune responses and typically require continuous or repeated administration of immunosuppressive or biologic disease-modifying drugs. Although generally effective, these therapies can cause both short- and long-term side effects and may fail to control the disease with risk of irreversible tissue damage. For such patients, haematopoietic stem cell transplantation (HSCT) has been successfully employed over the past 30 years, but this procedure requires caution due to significant side effects. To address these aspects, updated recommendations for the use of HSCT in RMDs have been developed in collaboration with an international expert panel from the European Society for Blood and Marrow Transplantation (EBMT). The panel reviewed all available evidence regarding HSCT application since 2004. Based on this review, EBMT expert-based consensus recommendations were formulated to guide best practices and ensure high-quality patient care. These recommendations include detailed indications, contraindications, and cautionary notes specific to each RMD, along with comprehensive protocols for diagnostic work-up. They are intended to support clinicians, scientists, patients, and caregivers in the field of RMDs.<\/jats:p>","DOI":"10.1038\/s41409-025-02695-y","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T22:33:59Z","timestamp":1755642839000},"page":"1451-1464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0097","authenticated-orcid":false,"given":"Tobias","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-170X","authenticated-orcid":false,"given":"Elisa","family":"Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1549-8852","authenticated-orcid":false,"given":"Nicoletta","family":"Del Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-1352","authenticated-orcid":false,"given":"Dominique","family":"Farge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-5875","authenticated-orcid":false,"given":"Zora","family":"Marjanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5639-0138","authenticated-orcid":false,"given":"Mathieu","family":"Puyade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-3476","authenticated-orcid":false,"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-312X","authenticated-orcid":false,"given":"Julia","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeska K.","family":"de Vries-Bouwstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-3474","authenticated-orcid":false,"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-2765","authenticated-orcid":false,"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5519-9154","authenticated-orcid":false,"given":"Isabel","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0922-4145","authenticated-orcid":false,"given":"Richard","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-4983","authenticated-orcid":false,"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-2222","authenticated-orcid":false,"given":"Maria Carolina","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-204X","authenticated-orcid":false,"given":"Gr\u00e9gory","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Rimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"2695_CR1","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023: e594-e610. https:\/\/doi.org\/10.1016\/s2665-9913(23)00211-4.","DOI":"10.1016\/s2665-9913(23)00211-4"},{"key":"2695_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18:22\u201334. https:\/\/doi.org\/10.1038\/s41584-021-00718-8.","journal-title":"Nat Rev Rheumatol"},{"key":"2695_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17:515\u201332. https:\/\/doi.org\/10.1038\/s41584-021-00668-1.","journal-title":"Nat Rev Rheumatol"},{"key":"2695_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nature03723","volume":"435","author":"JD Rioux","year":"2005","unstructured":"Rioux JD, Abbas AK. Paths to understanding the genetic basis of autoimmune disease. Nature. 2005;435:584\u20139. https:\/\/doi.org\/10.1038\/nature03723.","journal-title":"Nature"},{"key":"2695_CR5","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0030297","volume":"3","author":"D McGonagle","year":"2006","unstructured":"McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:e297 https:\/\/doi.org\/10.1371\/journal.pmed.0030297.","journal-title":"PLoS Med"},{"key":"2695_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/s0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic sclerosis. Lancet. 2023;401:304\u201318. https:\/\/doi.org\/10.1016\/s0140-6736(22)01692-0.","journal-title":"Lancet"},{"key":"2695_CR7","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/s0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet. 2024;403:2326\u201338. https:\/\/doi.org\/10.1016\/s0140-6736(24)00398-2.","journal-title":"Lancet"},{"key":"2695_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Prim. 2021;7:86 https:\/\/doi.org\/10.1038\/s41572-021-00321-x.","journal-title":"Nat Rev Dis Prim"},{"key":"2695_CR9","doi-asserted-by":"publisher","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, \u010coli\u0107 J, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2024. https:\/\/doi.org\/10.1136\/ard-2024-226430.","DOI":"10.1136\/ard-2024-226430"},{"key":"2695_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S-C, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30\u201347. https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41584-021-00601-6","volume":"17","author":"P Maschmeyer","year":"2021","unstructured":"Maschmeyer P, Chang HD, Cheng Q, Mashreghi MF, Hiepe F, Alexander T, et al. Immunological memory in rheumatic inflammation - a roadblock to tolerance induction. Nat Rev Rheumatol. 2021;17:291\u2013305. https:\/\/doi.org\/10.1038\/s41584-021-00601-6.","journal-title":"Nat Rev Rheumatol"},{"key":"2695_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","volume":"57","author":"T Alexander","year":"2022","unstructured":"Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2022;57:1055\u201362. https:\/\/doi.org\/10.1038\/s41409-022-01702-w.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","volume":"13","author":"JF Swart","year":"2017","unstructured":"Swart JF, Delemarre EM, van Wijk F, Boelens JJ, Kuball J, van Laar JM, et al. Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol. 2017;13:244\u201356. https:\/\/doi.org\/10.1038\/nrrheum.2017.7.","journal-title":"Nat Rev Rheumatol"},{"key":"2695_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217\u201339. https:\/\/doi.org\/10.1038\/s41409-022-01691-w.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/bmt.2011.185","volume":"47","author":"JA Snowden","year":"2012","unstructured":"Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2012;47:770\u201390. https:\/\/doi.org\/10.1038\/bmt.2011.185.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102476","volume":"69","author":"R Greco","year":"2024","unstructured":"Greco R, Alexander T, Del Papa N, Muller F, Saccardi R, Sanchez-Guijo F, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. eClinicalMedicine. 2024;69:102476 https:\/\/doi.org\/10.1016\/j.eclinm.2024.102476.","journal-title":"eClinicalMedicine"},{"key":"2695_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","volume":"58","author":"I Yakoub-Agha","year":"2023","unstructured":"Yakoub-Agha I, Greco R, Onida F, de la Camara R, Ciceri F, Corbacioglu S, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transpl. 2023;58:696\u2013700. https:\/\/doi.org\/10.1038\/s41409-023-01958-w.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/bmt.2014.251","volume":"50","author":"T Alexander","year":"2015","unstructured":"Alexander T, Bondanza A, Muraro PA, Greco R, Saccardi R, Daikeler T, et al. SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transpl. 2015;50:173\u201380. https:\/\/doi.org\/10.1038\/bmt.2014.251.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2017.56","volume":"52","author":"D Farge","year":"2017","unstructured":"Farge D, Burt RK, Oliveira MC, Mousseaux E, Rovira M, Marjanovic Z, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transpl. 2017;52:1495\u2013503. https:\/\/doi.org\/10.1038\/bmt.2017.56.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"B Sharrack","year":"2020","unstructured":"Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transpl. 2020;55:283\u2013306. https:\/\/doi.org\/10.1038\/s41409-019-0684-0.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","volume":"26","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transpl. 2020;26:1247\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.002.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2695_CR24","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1136\/ard.2010.148049","volume":"70","author":"GG Illei","year":"2011","unstructured":"Illei GG, Cervera R, Burt RK, Doria A, Hiepe F, Jayne D, et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:2071\u20134. https:\/\/doi.org\/10.1136\/ard.2010.148049.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR25","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","volume":"1","author":"JA Snowden","year":"2017","unstructured":"Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1:2742\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2017010041.","journal-title":"Blood Adv"},{"key":"2695_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1146\/annurev-med-070119-115617","volume":"72","author":"T Alexander","year":"2021","unstructured":"Alexander T, Greco R, Snowden JA. Hematopoietic stem cell transplantation for autoimmune disease. Annu Rev Med. 2021;72:215\u201328. https:\/\/doi.org\/10.1146\/annurev-med-070119-115617.","journal-title":"Annu Rev Med"},{"key":"2695_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2009.013458","volume":"95","author":"D Farge","year":"2010","unstructured":"Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on autoimmune diseases. Haematologica. 2010;95:284\u201392. https:\/\/doi.org\/10.3324\/haematol.2009.013458.","journal-title":"Haematologica"},{"key":"2695_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","volume":"79","author":"S van Bijnen","year":"2020","unstructured":"van Bijnen S, de Vries-Bouwstra J, van den Ende CH, Boonstra M, Kroft L, Geurts B, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Ann Rheum Dis. 2020;79:1084\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217058.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR29","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, de la C\u00e1mara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651\u201364. https:\/\/doi.org\/10.1038\/s41409-021-01227-8.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/0961203312470729","volume":"22","author":"B Alchi","year":"2013","unstructured":"Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T, et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus. 2013;22:245\u201353. https:\/\/doi.org\/10.1177\/0961203312470729.","journal-title":"Lupus"},{"key":"2695_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","volume":"106","author":"J Henes","year":"2021","unstructured":"Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 2021;106:375\u201383. https:\/\/doi.org\/10.3324\/haematol.2019.230128.","journal-title":"Haematologica"},{"key":"2695_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/bmt.2015.299","volume":"51","author":"MC Oliveira","year":"2016","unstructured":"Oliveira MC, Labopin M, Henes J, Moore J, Del Papa N, Cras A, et al. Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transpl. 2016;51:501\u20135. https:\/\/doi.org\/10.1038\/bmt.2015.299.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR33","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/art.10495","volume":"46","author":"J Moore","year":"2002","unstructured":"Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum. 2002;46:2301\u20139. https:\/\/doi.org\/10.1002\/art.10495.","journal-title":"Arthritis Rheum"},{"key":"2695_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/s0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498\u2013506. https:\/\/doi.org\/10.1016\/s0140-6736(11)60982-3.","journal-title":"Lancet"},{"key":"2695_CR35","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490\u20138. https:\/\/doi.org\/10.1001\/jama.2014.6368.","journal-title":"JAMA"},{"key":"2695_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35\u201347. https:\/\/doi.org\/10.1056\/nejmoa1703327.","journal-title":"N Engl J Med"},{"key":"2695_CR37","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41409-021-01355-1","volume":"56","author":"N Ait Abdallah","year":"2021","unstructured":"Ait Abdallah N, Wang M, Lansiaux P, Puyade M, Berthier S, Terriou L, et al. Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. Bone Marrow Transpl. 2021;56:2259\u201367. https:\/\/doi.org\/10.1038\/s41409-021-01355-1.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/rheumatology\/ket464","volume":"53","author":"JC Henes","year":"2014","unstructured":"Henes JC, Koetter I, Horger M, Schmalzing M, Mueller K, Eick C, et al. Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology. 2014;53:919\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/ket464.","journal-title":"Rheumatology"},{"key":"2695_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","volume":"56","author":"RK Burt","year":"2021","unstructured":"Burt RK, Han X, Quigley K, Arnautovic I, Shah SJ, Lee DC, et al. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. Bone Marrow Transpl. 2021;56:50\u20139. https:\/\/doi.org\/10.1038\/s41409-020-0978-2.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR40","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10067-017-3954-5","volume":"37","author":"G Helbig","year":"2018","unstructured":"Helbig G, Widuchowska M, Koclega A, Kopinska A, Kopec-Medrek M, Gawel WB, et al. Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis. Clin Rheumatol. 2018;37:1709\u201314. https:\/\/doi.org\/10.1007\/s10067-017-3954-5.","journal-title":"Clin Rheumatol"},{"key":"2695_CR41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.295.5.527","volume":"295","author":"RK Burt","year":"2006","unstructured":"Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006;295:527\u201335. https:\/\/doi.org\/10.1001\/jama.295.5.527.","journal-title":"JAMA"},{"key":"2695_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/ard.2007.070227","volume":"67","author":"L Statkute","year":"2008","unstructured":"Statkute L, Oyama Y, Barr WG, Sufit R, Ho S, Verda L, et al. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann Rheum Dis. 2008;67:991\u20137. https:\/\/doi.org\/10.1136\/ard.2007.070227.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR43","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41409-018-0173-x","volume":"53","author":"RK Burt","year":"2018","unstructured":"Burt RK, Han X, Gozdziak P, Yaung K, Morgan A, Clendenan AM, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. Bone Marrow Transpl. 2018;53:692\u2013700. https:\/\/doi.org\/10.1038\/s41409-018-0173-x.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02383-3","author":"A Ismail","year":"2024","unstructured":"Ismail A, Nitti R, Sharrack B, Badoglio M, Ambron P, Labopin M, et al. ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP). Bone Marrow Transpl. 2024. https:\/\/doi.org\/10.1038\/s41409-024-02383-3.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR45","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","volume":"24","author":"R Shouval","year":"2018","unstructured":"Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A. Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Biol Blood Marrow Transpl. 2018;24:937\u201344. https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.020.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2695_CR46","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41409-021-01277-y","volume":"56","author":"RK Burt","year":"2021","unstructured":"Burt RK, Muraro PA, Farge D, Oliveira MC, Snowden JA, Saccardi R, et al. New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transpl. 2021;56:1509\u201317. https:\/\/doi.org\/10.1038\/s41409-021-01277-y.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR47","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1002\/art.22256","volume":"54","author":"RK Burt","year":"2006","unstructured":"Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum. 2006;54:3750\u201360. https:\/\/doi.org\/10.1002\/art.22256.","journal-title":"Arthritis Rheum"},{"key":"2695_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.revmed.2023.12.008","volume":"45","author":"D Farge","year":"2024","unstructured":"Farge D, Pugnet G, Allez M, Castilla-Llorente C, Chatelus E, Cintas P, et al. French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases. Rev Med Interne. 2024;45:79\u201399. https:\/\/doi.org\/10.1016\/j.revmed.2023.12.008.","journal-title":"Rev Med Interne"},{"key":"2695_CR49","doi-asserted-by":"crossref","unstructured":"Burt RK, Farge D, Ruiz MA, Saccardi R, Snowden JA. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases. 2021; eBook: 978-1-315-15136-6: https:\/\/www.routledge.com\/Hematopoietic-Stem-Cell-Transplantation-and-Cellular-Therapies-for-Autoimmune\/Burt-Farge-Ruiz-Saccardi-Snowden\/p\/book\/978113855855.","DOI":"10.1201\/9781315151366"},{"key":"2695_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae268","author":"S Keret","year":"2024","unstructured":"Keret S, Chutko B, Dobrecky-Mery I, Wolak A, Hardak E, Slobodin G, et al. Cardiac safe hematopoietic stem cell transplantation protocol for systemic sclerosis with myocarditis- a two-step approach. Rheumatology. 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae268.","journal-title":"Rheumatology"},{"key":"2695_CR51","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/bmt.2012.67","volume":"47","author":"J Moore","year":"2012","unstructured":"Moore J, Englert H, Furlong T, Poon T, Milliken S, Ma D. Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide. Bone Marrow Transpl. 2012;47:1486\u20137. https:\/\/doi.org\/10.1038\/bmt.2012.67.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR52","doi-asserted-by":"crossref","unstructured":"In: Sureda A, Corbacioglu S, Greco R, Kroger N, Carreras E (eds). The EBMT handbook: hematopoietic cell transplantation and cellular therapies, 8th ed. Cham (CH); 2024.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"2695_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2021","unstructured":"Volkmann ER, Fischer A. Update on morbidity and mortality in systemic sclerosis-related interstitial lung disease. J Scleroderma Relat Disord. 2021;6:11\u201320. https:\/\/doi.org\/10.1177\/2397198320915042.","journal-title":"J Scleroderma Relat Disord"},{"key":"2695_CR54","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76:1897\u2013905. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211448.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR55","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landew\u00e9 R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620\u20138. https:\/\/doi.org\/10.1136\/ard.2008.096677.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR56","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","volume":"78","author":"M Becker","year":"2019","unstructured":"Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Ann Rheum Dis. 2019;78:1242\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215145.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR57","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1093\/rheumatology\/keae268","volume":"63","author":"S Keret","year":"2024","unstructured":"Keret S, Chutko B, Dobrecky-Mery I, Wolak A, Hardak E, Slobodin G, et al. Cardiac safe hematopoietic stem cell transplantation protocol for systemic sclerosis with myocarditis-a two-step approach. Rheumatology. 2024;63:e328\u2013e330. https:\/\/doi.org\/10.1093\/rheumatology\/keae268.","journal-title":"Rheumatology"},{"key":"2695_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","volume":"112","author":"M Zen","year":"2023","unstructured":"Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study. Eur J Intern Med. 2023;112:45\u201351. https:\/\/doi.org\/10.1016\/j.ejim.2023.02.004.","journal-title":"Eur J Intern Med"},{"key":"2695_CR59","doi-asserted-by":"publisher","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021; 8. https:\/\/doi.org\/10.1136\/lupus-2021-000538.","DOI":"10.1136\/lupus-2021-000538"},{"key":"2695_CR60","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75:1615\u201321. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207726.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR61","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/s2665-9913(22)00304-6","volume":"4","author":"R Kandane-Rathnayake","year":"2022","unstructured":"Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, et al. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. Lancet Rheumatol. 2022;4:e822\u2013e830. https:\/\/doi.org\/10.1016\/s2665-9913(22)00304-6.","journal-title":"Lancet Rheumatol"},{"key":"2695_CR62","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard-2022-222487","volume":"81","author":"MF Ugarte-Gil","year":"2022","unstructured":"Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, et al. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022;81:1541\u20138. https:\/\/doi.org\/10.1136\/ard-2022-222487.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR63","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1191\/0961203304lu525oa","volume":"13","author":"D Jayne","year":"2004","unstructured":"Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13:168\u201376. https:\/\/doi.org\/10.1191\/0961203304lu525oa.","journal-title":"Lupus"},{"key":"2695_CR64","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","volume":"113","author":"T Alexander","year":"2009","unstructured":"Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113:214\u201323. https:\/\/doi.org\/10.1182\/blood-2008-07-168286.","journal-title":"Blood"},{"key":"2695_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1\u201311. https:\/\/doi.org\/10.1002\/art.37715.","journal-title":"Arthritis Rheum"},{"key":"2695_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101845","volume":"37","author":"T Ecclestone","year":"2023","unstructured":"Ecclestone T, Watts RA. Classification and epidemiology of vasculitis: emerging concepts. Best Pract Res Clin Rheumatol. 2023;37:101845 https:\/\/doi.org\/10.1016\/j.berh.2023.101845.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2695_CR67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105591","volume":"90","author":"T Machet","year":"2023","unstructured":"Machet T, Qu\u00e9meneur T, Ledoult E, Mesbah R, Lebas C, Hachulla E, et al. Rituximab resistance at 3months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: a French multicentre retrospective study in 116 patients. Jt Bone Spine. 2023;90:105591 https:\/\/doi.org\/10.1016\/j.jbspin.2023.105591.","journal-title":"Jt Bone Spine"},{"key":"2695_CR69","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3899\/jrheum.2022-1214","volume":"50","author":"MJ Samec","year":"2023","unstructured":"Samec MJ, Rakholiya J, Langenfeld H, Crowson CS, Abril A, Wang B, et al. Relapse risk and safety of long-term tocilizumab use among patients with giant cell arteritis: a single-enterprise cohort study. J Rheumatol. 2023;50:1310\u20137. https:\/\/doi.org\/10.3899\/jrheum.2022-1214.","journal-title":"J Rheumatol"},{"key":"2695_CR70","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/s41409-020-0907-4","volume":"55","author":"C Laurent","year":"2020","unstructured":"Laurent C, Marjanovic Z, Ricard L, Henes J, Dulery R, Badoglio M, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2020;55:2109\u201313. https:\/\/doi.org\/10.1038\/s41409-020-0907-4.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638709","volume":"12","author":"M Puyade","year":"2021","unstructured":"Puyade M, Patel A, Lim YJ, Blank N, Badoglio M, Gualandi F, et al. Autologous hematopoietic stem cell transplantation for Beh\u00e7et\u2019s disease: a retrospective survey of patients treated in europe, on behalf of the autoimmune diseases working party of the European Society for Blood and Marrow Transplantation. Front Immunol. 2021;12:638709 https:\/\/doi.org\/10.3389\/fimmu.2021.638709.","journal-title":"Front Immunol"},{"key":"2695_CR72","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41409-019-0763-2","volume":"55","author":"T Alexander","year":"2020","unstructured":"Alexander T, Samuelson C, Daikeler T, Henes J, Akil M, Skagerlind L, et al. Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. Bone Marrow Transpl. 2020;55:1512\u20135. https:\/\/doi.org\/10.1038\/s41409-019-0763-2.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR73","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","volume":"8","author":"C Gurnari","year":"2024","unstructured":"Gurnari C, Koster L, Baaij L, Heiblig M, Yakoub-Agha I, Collin M, et al. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT. Blood Adv. 2024;8:1444\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2023012478.","journal-title":"Blood Adv"},{"key":"2695_CR74","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR75","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/art.41762","volume":"73","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE. Expert perspective: management of refractory inflammatory myopathy. Arthritis Rheumatol. 2021;73:1394\u2013407. https:\/\/doi.org\/10.1002\/art.41762.","journal-title":"Arthritis Rheumatol"},{"key":"2695_CR76","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03009740903096622","volume":"39","author":"U Holzer","year":"2010","unstructured":"Holzer U, van Royen-Kerkhof A, van der Torre P, Kuemmerle-Deschner J, Well C, Handgretinger R, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol. 2010;39:88\u201392. https:\/\/doi.org\/10.3109\/03009740903096622.","journal-title":"Scand J Rheumatol"},{"key":"2695_CR77","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12969-018-0284-3","volume":"16","author":"J Zhu","year":"2018","unstructured":"Zhu J, Su G, Lai J, Dong B, Kang M, Li S, et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study. Pediatr Rheumatol Online J. 2018;16:72 https:\/\/doi.org\/10.1186\/s12969-018-0284-3.","journal-title":"Pediatr Rheumatol Online J"},{"key":"2695_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80:31\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR79","first-page":"482","volume":"31","author":"JA Snowden","year":"2004","unstructured":"Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol. 2004;31:482\u20138.","journal-title":"J Rheumatol"},{"key":"2695_CR80","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/sj.bmt.1702435","volume":"25","author":"F Lanza","year":"2000","unstructured":"Lanza F, Dominici M, Govoni M, Moretti S, Campioni D, Corte RL, et al. Prolonged remission state of refractory adult onset Still\u2019s disease following CD34-selected autologous peripheral blood stem cell transplantation. Bone Marrow Transpl. 2000;25:1307\u201310. https:\/\/doi.org\/10.1038\/sj.bmt.1702435.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR81","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"key":"2695_CR82","doi-asserted-by":"publisher","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2024. https:\/\/doi.org\/10.1016\/s2665-9913(24)00282-0.","DOI":"10.1016\/s2665-9913(24)00282-0"},{"key":"2695_CR83","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander T, Kr\u00f6nke J, Cheng Q, Keller U, Kr\u00f6nke G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N Engl J Med. 2024;391:864\u20136. https:\/\/doi.org\/10.1056\/NEJMc2407150.","journal-title":"N Engl J Med"},{"key":"2695_CR84","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen M, Bucci L, B\u00f6ltz S, N\u00f6thling DM, Rothe T, Anoshkin K, et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N Engl J Med. 2024;391:867\u20139. https:\/\/doi.org\/10.1056\/NEJMc2408786.","journal-title":"N Engl J Med"},{"key":"2695_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.043","author":"E Siegert","year":"2025","unstructured":"Siegert E, Biesen R, Dzamukova M, Furth C, Probst M, Doellinger F, et al. Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation. Ann Rheum Dis. 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.01.043.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR86","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"key":"2695_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100283","volume":"3","author":"T Alexander","year":"2024","unstructured":"Alexander T, Tassy N, Domenech A, Kramer E, Jessop H, Kenyon M, et al. Patient-reported outcomes in HSCT for autoimmune diseases: considerations on behalf of the EBMT ADWP, PAC, and Nurses Group. J Allergy Clin Immunol Glob. 2024;3:100283 https:\/\/doi.org\/10.1016\/j.jacig.2024.100283.","journal-title":"J Allergy Clin Immunol Glob"},{"key":"2695_CR88","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1056\/NEJMp2409329","volume":"391","author":"A Hantel","year":"2024","unstructured":"Hantel A, Hibbs SP, Merz LE, Abel GA. The duffy null phenotype - addressing a source of discrimination in cancer care. N Engl J Med. 2024;391:1969\u201372. https:\/\/doi.org\/10.1056\/NEJMp2409329.","journal-title":"N Engl J Med"},{"key":"2695_CR89","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/jac\/dkw157","volume":"71","author":"J Maertens","year":"2016","unstructured":"Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397\u2013404. https:\/\/doi.org\/10.1093\/jac\/dkw157.","journal-title":"J Antimicrob Chemother"},{"key":"2695_CR90","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S1473-3099(23)00495-4","volume":"24","author":"R Aerts","year":"2024","unstructured":"Aerts R, Mehra V, Groll AH, Martino R, Lagrou K, Robin C, et al. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022. Lancet Infect Dis. 2024;24:e291\u2013e306. https:\/\/doi.org\/10.1016\/S1473-3099(23)00495-4.","journal-title":"Lancet Infect Dis"},{"key":"2695_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01326-6","author":"R Greco","year":"2021","unstructured":"Greco R, Alexander T, Burman J, Del Papa N, de Vries-Bouwstra J, Farge D, et al. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transpl. 2021. https:\/\/doi.org\/10.1038\/s41409-021-01326-6.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR92","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7861\/clinmedicine.18-4-329","volume":"18","author":"JA Snowden","year":"2018","unstructured":"Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist. Clin Med. 2018;18:329\u201334. https:\/\/doi.org\/10.7861\/clinmedicine.18-4-329.","journal-title":"Clin Med"},{"key":"2695_CR93","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1016\/j.vaccine.2021.07.022","volume":"39","author":"H Colton","year":"2021","unstructured":"Colton H, Greenfield DM, Snowden JA, Miller PDE, Morley NJ, Wright J, et al. Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant. Vaccine. 2021;39:4778\u201383. https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.022.","journal-title":"Vaccine"},{"key":"2695_CR94","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41409-024-02461-6","volume":"60","author":"T Alexander","year":"2025","unstructured":"Alexander T, Badoglio M, Labopin M, Daikeler T, Farge D, Kazmi M, et al. Monitoring and management of CMV and EBV after autologous haematopoietic stem cell transplantation for autoimmune diseases: a survey of the EBMT Autoimmune Diseases Working party (ADWP). Bone Marrow Transpl. 2025;60:110\u20133. https:\/\/doi.org\/10.1038\/s41409-024-02461-6.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR95","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/cid\/ciz047","volume":"69","author":"V Mehra","year":"2019","unstructured":"Mehra V, Rhone E, Widya S, Zuckerman M, Potter V, Raj K, et al. Epstein-Barr virus and monoclonal gammopathy of clinical significance in autologous stem cell transplantation for multiple sclerosis. Clin Infect Dis. 2019;69:1757\u201363. https:\/\/doi.org\/10.1093\/cid\/ciz047.","journal-title":"Clin Infect Dis"},{"key":"2695_CR96","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41409-022-01863-8","volume":"58","author":"S Cesaro","year":"2023","unstructured":"Cesaro S, Ljungman P, Tridello G, Mikulska M, Wendel L, Styczynski J, et al. New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT. Bone Marrow Transpl. 2023;58:203\u20138. https:\/\/doi.org\/10.1038\/s41409-022-01863-8.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109709","volume":"254","author":"J Massey","year":"2023","unstructured":"Massey J, Artuz C, Dyer Z, Jackson K, Khoo M, Visweswaran M, et al. Diversification and expansion of the EBV-reactive cytotoxic T lymphocyte repertoire following autologous haematopoietic stem cell transplant for multiple sclerosis. Clin Immunol. 2023;254:109709 https:\/\/doi.org\/10.1016\/j.clim.2023.109709.","journal-title":"Clin Immunol"},{"key":"2695_CR98","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41409-023-02190-2","volume":"59","author":"SJ Rotz","year":"2024","unstructured":"Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, et al. International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update. Bone Marrow Transpl. 2024;59:717\u201341. https:\/\/doi.org\/10.1038\/s41409-023-02190-2.","journal-title":"Bone Marrow Transpl"},{"key":"2695_CR99","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1182\/blood-2011-02-336156","volume":"118","author":"T Daikeler","year":"2011","unstructured":"Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011;118:1693\u20138. https:\/\/doi.org\/10.1182\/blood-2011-02-336156.","journal-title":"Blood"},{"key":"2695_CR100","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","volume":"10","author":"NS Majhail","year":"2017","unstructured":"Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10:220\u20137. https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.009.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2695_CR101","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jtct.2023.12.001","volume":"30","author":"SJ Rotz","year":"2024","unstructured":"Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, et al. International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update. Transpl Cell Ther. 2024;30:349\u201385. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.001.","journal-title":"Transpl Cell Ther"},{"key":"2695_CR102","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1586\/17474086.2013.816507","volume":"6","author":"A Tichelli","year":"2013","unstructured":"Tichelli A, Rovo A. Fertility issues following hematopoietic stem cell transplantation. Expert Rev Hematol. 2013;6:375\u201388. https:\/\/doi.org\/10.1586\/17474086.2013.816507.","journal-title":"Expert Rev Hematol"},{"key":"2695_CR103","doi-asserted-by":"publisher","first-page":"665","DOI":"10.6002\/ect.2015.0336","volume":"14","author":"M Maciejewska","year":"2016","unstructured":"Maciejewska M, Snarski E, Wiktor-Jedrzejczak W. A preliminary online study on menstruation recovery in women after autologous hematopoietic stem cell transplant for autoimmune diseases. Exp Clin Transpl. 2016;14:665\u20139. https:\/\/doi.org\/10.6002\/ect.2015.0336.","journal-title":"Exp Clin Transpl"},{"key":"2695_CR104","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR105","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1016\/s2665-9913(23)00212-6","volume":"5","author":"A Lescoat","year":"2023","unstructured":"Lescoat A, Bellando-Randone S, Campochiaro C, Del Galdo F, Denton CP, Farrington S, et al. Beyond very early systemic sclerosis: deciphering pre\u2011scleroderma and its trajectories to open new avenues for preventive medicine. Lancet Rheumatol. 2023;5:e683\u2013e694. https:\/\/doi.org\/10.1016\/s2665-9913(23)00212-6.","journal-title":"Lancet Rheumatol"},{"key":"2695_CR106","doi-asserted-by":"publisher","first-page":"e044483","DOI":"10.1136\/bmjopen-2020-044483","volume":"11","author":"J Spierings","year":"2021","unstructured":"Spierings J, van Rhenen A, Welsing PM, Marijnissen AC, De Langhe E, Del Papa N, et al. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open. 2021;11:e044483 https:\/\/doi.org\/10.1136\/bmjopen-2020-044483.","journal-title":"BMJ Open"},{"key":"2695_CR107","first-page":"84","volume":"25","author":"DE Furst","year":"1998","unstructured":"Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D\u2019Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1998;25:84\u20138.","journal-title":"J Rheumatol"},{"key":"2695_CR108","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/art.1780401110","volume":"40","author":"VD Steen","year":"1997","unstructured":"Steen VD, Medsger TA Jr. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40:1984\u201391. https:\/\/doi.org\/10.1002\/art.1780401110.","journal-title":"Arthritis Rheum"},{"key":"2695_CR109","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214819.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR110","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","volume":"44","author":"DA Isenberg","year":"2005","unstructured":"Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44:902\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/keh624.","journal-title":"Rheumatology"},{"key":"2695_CR111","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288\u201391.","journal-title":"J Rheumatol"},{"key":"2695_CR112","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","volume":"78","author":"D Jesus","year":"2019","unstructured":"Jesus D, Matos A, Henriques C, Zen M, Larosa M, Iaccarino L, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019;78:365\u201371. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214502.","journal-title":"Ann Rheum Dis"},{"key":"2695_CR113","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363\u20139. https:\/\/doi.org\/10.1002\/art.1780390303.","journal-title":"Arthritis Rheum"},{"key":"2695_CR114","doi-asserted-by":"publisher","first-page":"431","DOI":"10.21037\/atm-20-5048","volume":"9","author":"S Chakka","year":"2021","unstructured":"Chakka S, Krain RL, Concha JSS, Chong BF, Merola JF, Werth VP. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med. 2021;9:431 https:\/\/doi.org\/10.21037\/atm-20-5048.","journal-title":"Ann Transl Med"},{"key":"2695_CR115","first-page":"671","volume":"87","author":"RA Luqmani","year":"1994","unstructured":"Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671\u20138.","journal-title":"QJM"},{"key":"2695_CR116","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371\u201380. https:\/\/doi.org\/10.1002\/art.1780400222.","journal-title":"Arthritis Rheum"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02695-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02695-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02695-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:20:19Z","timestamp":1762183219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02695-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":116,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02695-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TA received Honoria from Abbvie, Amgen, AstraZeneca and GSK study support from Johnson & Johnson. RG discloses speaking honoraria from Biotest, Pfizer, Medac, Neovii, Kyverna and Magenta. RB is CEO of Genani Corporation, Chicago, Illinois. FM received honoraria & Travel Support from BMS, Janssen, Kite\/Gilead, Miltenyi, Novartis, Received Research Support from Kite\/Gilead. JAS discloses consultancy for BMS, Medac, Vertex and Jazz. JH discloses consultancy for Miltenyi and Neovii. JS discloses research support from Boehringer Ingelheim and Miltenyi. RC discloses consultancy for AstraZeneca, Celgene, GSK, Janssen, ElyLilly, Pfizer, UCB, Rubi\u00f3 and Werfen. PA reports no conflict of interest; he discloses travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis and consulting to Magenta Therapeutics, Jasper Therapeutics and Cellerys AG. ER discloses speaking honoraria by Janssen Pharmaceutica. AR discloses speaker honoraria from Gilead. The remaining authors have nothing to declare. JM discloses speaker honoria from Medac and Pfizer. JVR discloses speaker honoraria from Janssen-Cilag, Boehringer-Ingelheim, Pfizer, AstraZeneca, BMS, UCB; consultancy honoraria from Abbvie, Janssen, Boehringer- Ingelheim, and grant\/research support from ReumaNederland, Janssen-Cilag, Galapagos, Roche; all payments were made to the institution. GP reports no conflict of interest; he discloses travel support and speaker honoraria from Abbvie, Astra-Zeneca, Novartis, Amgen, GSK, Pfizer, Boehringer Ingelheim, Amicus. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by the Autoimmune Diseases Working Party of the EBMT.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}